Late last year, the therapy developers dosed their first patient following positive preclinical data demonstrating safety and ...

Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - - Strengthened balance sheet with net proceeds ...

Capricor officials said the company was prepared for the meeting and does not expect it to delay the FDA’s decision on the ...

MEDFORD, Ore.- A fundraiser held at the Children’s Museum of Southern Oregon raises thousands of dollars to help a local boy ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – ...

We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San ...

Fundraiser for Maverick” has been set up to reunite siblings in a race against time. Maverick’s Duchenne Muscular Dystrophy ...

Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...

Shares of WAVE Life Sciences were trading at $6.41 as of May 06. Over the last 52-week period, shares are up 14.67%. Given ...